不可逆电穿孔治疗局限性前列腺癌下调免疫抑制并诱导全身抗肿瘤T细胞活化——IRE-IMMUNO研究
这项前瞻性研究比较了不可逆电穿孔(IRE)与机器人辅助根治性前列腺切除术(RARP)在局限性中危前列腺癌患者中诱导的全身抗肿瘤免疫反应。30例患者接受IRE(n=20)或RARP(n=10),于治疗前及治疗后5、14、30天采集外周血。IRE诱导调节性T细胞耗竭并增加活化CTLA-4+CD4+和CD8+T细胞,峰值在IRE后14天,且与肿瘤体积/消融大小正相关;8例免疫健全患者中4例出现PSAP和/或NY-ESO-1特异性T细胞反应扩展。RARP后髓源性抑制细胞频率暂时性增加。结论认为IRE诱导前列腺癌特异性全身免疫反应,联合CTLA-4检查点抑制可能进一步增强疗效。
要点
- IRE治疗后调节性T细胞耗竭(P=0.0001),活化CTLA-4+CD4+(P<0.001)和CD8+(P=0.032)T细胞增加,峰值在14天。
- IRE诱导的免疫效应与肿瘤体积/消融大小正相关;8例免疫健全患者中4例出现PSAP和/或NY-ESO-1特异性T细胞反应扩展。
- RARP后活化髓源性抑制细胞频率暂时性增加(P=0.047),符合短暂免疫抑制。
核心结论
- IRE在局限性前列腺癌患者中诱导前列腺癌特异性全身免疫反应,有助于将肿瘤微环境转化为更允许免疫的状态。
- 联合CTLA-4检查点抑制可能进一步增强疗效,或为高危局限性或(寡)转移性疾病开辟新的协同治疗范式。
研究设计与样本
- 前瞻性比较研究,2021年2月至2022年6月纳入30例局限性中危前列腺癌患者,治疗前及治疗后5、14、30天采集外周血。
- 纳入标准为国际泌尿病理学会分级2-3级、临床分期≤T2c、前列腺特异性抗原<20 ng/mL。
- 患者接受IRE(n=20)或RARP(n=10);采用流式细胞术检测淋巴细胞和髓系免疫细胞亚群频率及活化状态,以干扰素-γ酶联免疫斑点法检测对前列腺酸性磷酸酶(PSAP)和癌睾丸抗原NY-ESO-1的T细胞反应。
- 采用重复测量方差分析和双侧Student t检验比较免疫反应随时间及组间差异。
主要发现
- 两组患者及肿瘤特征相似,除年龄外(IRE中位68岁 vs RARP中位62岁,P=0.01)。
- IRE诱导全身调节性T细胞耗竭(P=0.0001),同时活化CTLA-4+CD4+(P<0.001)和CD8+(P=0.032)T细胞增加,峰值在IRE后14天。
- IRE的免疫效应与肿瘤体积/消融大小正相关;8例免疫健全患者中4例出现PSAP和/或NY-ESO-1特异性T细胞反应扩展。
- RARP后活化髓源性抑制细胞频率暂时性增加(P=0.047),符合短暂免疫抑制。
临床怎么用
- 作者认为IRE在局限性前列腺癌中诱导前列腺癌特异性全身免疫反应,有助于将肿瘤微环境转化为更允许免疫的状态。
- 作者提出联合CTLA-4检查点抑制可能进一步增强疗效,或为高危局限性或(寡)转移性疾病开辟新的协同治疗范式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To prospectively compare systemic anti-tumour immune responses induced by irreversible electroporation (IRE) and robot-assisted radical prostatectomy (RARP) in patients with localised intermediate-risk prostate cancer (PCa). PATIENTS AND METHODS: Between February 2021 and June 2022, before and after treatment (at 5, 14 and 30 days) peripheral blood samples of 30 patients with localised PCa were prospectively collected. Patient inclusion criteria were: International Society of Urological Pathologists Grade 2-3, clinical cancer stage ≤T2c, prostate-specific antigen level <20 ng/mL). Patients were treated with IRE (n = 20) or RARP (n = 10). Frequency and activation status of lymphocytic and myeloid immune cell subsets were determined using flow cytometry. PCa-specific T-cell responses to prostatic acid phosphatase (PSAP) and cancer testis antigen (New York oesophageal squamous cell carcinoma 1 [NY-ESO-1]) were determined by interferon-γ enzyme-linked immunospot assay (ELISpot). Repeated-measures analysis of variance and two-sided Student's t-tests were used to compare immune responses over time and between treatment cohorts. RESULTS: Patient and tumour characteristics were similar between the cohorts except for age (median 68 years [IRE] and 62 years [RARP], P = 0.01). IRE induced depletion of systemic regulatory T cells (P = 0.0001) and a simultaneous increase in activated cytotoxic T-lymphocyte antigen 4 (CTLA-4)+ cluster of differentiation (CD)4+ (P < 0.001) and CD8+ (P = 0.032) T cells, consistent with reduction of systemic immune suppression allowing for effector T-cell activation, peaking 14 days after IRE. Effects were positively correlated with tumour volume/ablation size. Accordingly, IRE induced expansion of PSAP and/or NY-ESO-1 specific T-cell responses in four of the eight immune competent patients. Temporarily increased activated myeloid derived suppressor cell frequencies (P = 0.047) were consistent with transient immunosuppression after RARP. CONCLUSIONS: Irreversible electroporation induces a PCa-specific systemic immune response in patients with localised PCa, aiding conversion of the tumour microenvironment into a more immune permissive state. Therapeutic efficacy might be further enhanced by combination with CTLA-4 checkpoint inhibition, potentially opening up a new synergistic treatment paradigm for high-risk localised or (oligo)metastatic disease.
引用
- Geboers B, Scheltema MJ, Jung J, et al. Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study. BJU Int. 2024. PMID: 39101639. doi:10.1111/bju.16496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。